Roberto Luksch

Istituti di Ricovero e Cura a Carattere Scientifico — Italy

Medicine · Health Sciences

52h-index8.9kcitations311works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(138), Sarcoma Diagnosis and Treatment(86), Childhood Cancer Survivors' Quality of Life(43), Cancer, Hypoxia, and Metabolism(38), Lung Cancer Research Studies(34)

Publications309 total

Pediatric palliative care in patients with brain tumors: Timing, activation, and management of acute events
Tumori Journal·2025
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group
Critical Reviews in Oncology/Hematology·2025· 2 citedOpen Access
Supplementary Table S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Table S1 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Table S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Appendix S1 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Figure S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Figure S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Table S2 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Figure S4 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Data from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Figure S1 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Table S4 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Figure S2 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison
Cancers·2025· 2 citedOpen Access
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials
Journal of Clinical Oncology·2025· 5 citedOpen Access
Successful management of Ewing Sarcoma in a pediatric patient: a case report on epiphyseal preservation and biological reconstruction
Orthoplastic Surgery·2025Open Access
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
Clinical Cancer Research·2025· 3 citedOpen Access
Pediatric Craniofacial Osteosarcoma: The Milano Experience
Pediatric Blood & Cancer·2025· 1 citedOpen Access
Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study.
Journal of Clinical Oncology·2025· 1 cited
page 1 of 16Next →

Frequent Co-authors

Andrea Ferrari(19), Maura Massimino(18), Michela Casanova(18), Filippo Spreafico(17), Monica Terenziani(17), Alberto Garaventa(15), Marta Podda(15), Graziella Cefalo(13), Franca Fossati‐Bellani(13), Lorenza Gandola(12), Paola Collini(12), Ruth Ladenstein(11), Cristina Meazza(11), Dominique Valteau‐Couanet(10), Geneviève Laureys(9), Daniela Polastri(9), Bruno De Bernardi(8), Victoria Castel(7), Maja Beck‐Popovic(7), Andrew D.J. Pearson(7)